Because JCR wanted to use Mesoblasts patents / IP, so they need to pay a Royalty among other things.
You can value that individual drug and individual use by multiplying the Japan revenue by 9 times, because the USA is at least 8 times the market size. This isn't a value stock though - it's a growth stock, so all published valuations will be typically incorrect if it succeeds because they factor in failure.
Ann: COVID-19/GVHD Update, Quarterly Report and Appendix 4C, page-126
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
-0.055(4.89%) |
Mkt cap ! $1.221B | |||
| Open | High | Low | Value | Volume |
| $1.14 | $1.16 | $1.06 | $8.816M | 8.055M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 280000 | $1.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.07 | 2000 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |